MAIA Biotechnology
MAIA Biotechnology develops telomere-targeting immunotherapies that enhance the immune system's ability to recognize and attack cancer cells. Their approach addresses the challenge of tumor evasion by leveraging novel mechanisms to improve treatment efficacy in oncology.
- Biotechnology
Funding
Raised to date
$950KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers evade the immune system, limiting the effectiveness of immunotherapies. Traditional cancer treatments often fail to fully eradicate tumors due to the cancer cells' ability to develop resistance mechanisms. This resistance leads to disease progression and poor patient outcomes.
Solution
MAIA Biotechnology is developing targeted immunotherapies focused on telomere biology to enhance the immune system's ability to recognize and eliminate cancer cells. Their approach aims to overcome tumor evasion by activating telomerase expression in cancer cells, making them more susceptible to immune-mediated killing. By specifically targeting telomeres, MAIA's therapies seek to disrupt the mechanisms that allow cancer cells to evade immune detection and destruction. This strategy has the potential to improve the efficacy of existing immunotherapies and provide a new treatment option for patients with advanced cancers.
Target Audience
The primary target audience includes patients with advanced cancers who have failed to respond to standard therapies, as well as oncologists and researchers seeking innovative approaches to cancer immunotherapy.
Features
- Telomere-targeting approach to selectively sensitize cancer cells to immunotherapy.
- Development of novel drug candidates that modulate telomerase activity.
- Focus on overcoming mechanisms of tumor resistance to immune checkpoint inhibitors.